A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06628622
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, Los Alamitos, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸iResearch Atlanta, Decatur, Georgia, United States
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
- Conditions
- Pyoderma Gangrenosum
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT06624670
- Locations
- 🇨🇳
Second Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China
🇨🇳Shanghai Skin Disease Hospital, Shanghai, China
🇨🇳The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
- Conditions
- Healthy
- Interventions
- Drug: Nerandomilast, Formulation 1Drug: Nerandomilast, Formulation 2
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT06624072
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT06619509
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China
🇨🇿University Hospital Olomouc, Olomouc, Czechia
🇩🇰Copenhagen University Hospital, Rigshospitalet, København Ø, Denmark
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 200
- Registration Number
- NCT06581432
- Locations
- 🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States
🇺🇸University of Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
🇺🇸Precision NextGen Oncology, Beverly Hills, California, United States
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 106
- Registration Number
- NCT06575400
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT06572111
- Locations
- 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06564441
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test Different Doses of BI 1569912 in People With Depression
- Conditions
- Depressive Disorder, Major
- Interventions
- Drug: Placebo matching BI 1569912
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 224
- Registration Number
- NCT06558344
- Locations
- 🇺🇸
Surburban Research Associates, Inc., Media, Pennsylvania, United States
🇺🇸Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach, California, United States
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- Conditions
- Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11000
- Registration Number
- NCT06531824
- Locations
- 🇺🇸
Apogee Clinical Research, Huntsville, Alabama, United States
🇺🇸Southwest Kidney Institute, Surprise, Arizona, United States
🇺🇸Total Research Group, LLC, Miami, Florida, United States